As the TIME is linked to prognosis and response to immunotherapy in cancer (Binnewies et al., 2018; Hinshaw and Shevde, 2019), we next examined the relationship between VSTM2L expression and immune cell infiltration (Figure 6, details are shown in Supplementary Figure S3) and the expression of immunomodulators in the TIME across 33 cancers extracted from TCGA datasets using TIMER. The gene discussed is VSTM2L; the disease is cancer.